Aduhelm Approved for Alzheimer's Disease

Aduhelm (aducanumab), developed by Biogen and Eisai, was approved by the U.S. Food and Drug Administration in June 2021, making it the first disease-modifying therapy for the treatment of Alzheimer’s disease. It is designed to reduce the number of amyloid plaques present in the brain, potentially slowing neurodegeneration and disease progression. Learn more about this therapy and its path to approval below.

Learn more
Aduhelm approved

FDA Approves Aduhelm, First Targeted Alzheimer’s Therapy

For the first time in almost 18 years, the U.S. Food and Drug Administration (FDA) has approved a new treatment — Aduhelm, also known as aducanumab — for Alzheimer’s disease, and a first targeted treatment for patients. With this approval, Aduhelm becomes the first disease-modifying therapy for Alzheimer’s, and…

Read more

Aduhelm Most Appropriate for Early-stage Alzheimer’s, Experts Say

Aduhelm (aducanumab), approved for Alzheimer’s disease in the U.S., is most appropriate for people with mild cognitive impairment (MCI) due to the disease or early Alzheimer’s dementia, the disorders for which it was tested in clinical trials and subsequently approved, according to experts from the scientific community. The experts…